×
About 5,708 results

ALLMedicine™ Basal Cell Carcinoma Center

Research & Reviews  1,982 results

Reconstruction of Medial Canthal Defects by Local/Loco-Regional Flaps.
https://doi.org/10.1097/SCS.0000000000008146
The Journal of Craniofacial Surgery; Bhandari PS

Sep 13th, 2021 - To describe a series of medial canthal defect reconstruction by local/loco-regional flaps following excision of basal cell carcinoma. A series of 35 medial canthal defects following excision of basal cell carcinoma was reconstructed by local/loco-...

Evaluation of Watchful Waiting and Tumor Behavior in Patients With Basal Cell Carcinoma...
https://doi.org/10.1001/jamadermatol.2021.3020
JAMA Dermatology; van Winden MEC, Hetterschijt CRM et. al.

Sep 9th, 2021 - Few studies have examined watchful waiting (WW) in patients with basal cell carcinoma (BCC), although this approach might be suitable in patients who might not live long enough to benefit from treatment. To evaluate reasons for WW and to document ...

Clinical Evidence on "Watchful Waiting" in Basal Cell Carcinoma.
https://doi.org/10.1001/jamadermatol.2021.3019
JAMA Dermatology; Wehner MR

Sep 9th, 2021 - Clinical Evidence on "Watchful Waiting" in Basal Cell Carcinoma.|2021|Wehner MR,|

Immunohistochemical expression of SOX2 in non-melanoma skin cancer.
https://doi.org/10.1111/jocd.14433
Journal of Cosmetic Dermatology; Abdou AG, Mostafa AF et. al.

Sep 9th, 2021 - Basal cell carcinoma (BCC) followed by squamous cell carcinoma (SCC) are the most common non-melanoma skin cancer (NMSC). SOX2 is a transcription factor that acts on various phases of embryonic development and its overexpression in many tumors has...

Topical 5% 5-Fluorouracil versus procedural modalities for squamous cell carcinoma in s...
https://doi.org/10.1016/j.jaad.2021.08.045
Journal of the American Academy of Dermatology; Neale H, Michelon M et. al.

Sep 4th, 2021 - Topical 5% 5-Fluorouracil versus procedural modalities for squamous cell carcinoma in situ and superficial basal cell carcinoma: a retrospective cohort analysis.|2021|Neale H,Michelon M,Jacob S,Pinkston M,Ukaegbu R,|

see more →

Guidelines  7 results

Definitive and Postoperative Radiation Therapy for Basal and Squamous Cell Cancers of t...
https://doi.org/10.1016/j.prro.2019.10.014
Practical Radiation Oncology; Likhacheva A, Awan M et. al.

Dec 14th, 2019 - This guideline reviews the evidence for the use of definitive and postoperative radiation therapy (RT) in patients with basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC). The American Society for Radiation Oncology convened a...

Diagnosis and treatment of basal cell carcinoma: European consensus-based interdiscipli...
https://doi.org/10.1016/j.ejca.2019.06.003
European Journal of Cancer (Oxford, England : 1990); Peris K, Fargnoli MC et. al.

Jul 10th, 2019 - Basal cell carcinoma (BCC) is the most common malignant tumour in white populations. Multidisciplinary experts from the European Dermatology Forum, the European Association of Dermato-Oncology and the European Organization of Research and Treatmen...

Guidelines of care for the management of basal cell carcinoma.
https://doi.org/10.1016/j.jaad.2017.10.006
Journal of the American Academy of Dermatology; , et. al.

Jan 15th, 2018 - Basal cell carcinoma (BCC) is the most common form of human cancer, with a continually increasing annual incidence in the United States. When diagnosed early, the majority of BCCs are readily treated with office-based therapy, which is highly cura...

Non-melanoma skin cancer: United Kingdom National Multidisciplinary Guidelines.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4873942
The Journal of Laryngology and Otology; Newlands C, Currie R et. al.

Nov 15th, 2016 - This is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer patients in the UK. This paper provides consensus recommendations on the management of cutaneous basal cell carcinoma and squamous c...

Basal Cell Skin Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2016.0065
Journal of the National Comprehensive Cancer Network : JN... Bichakjian CK, Olencki T et. al.

May 11th, 2016 - Basal cell carcinoma (BCC) of the skin is the most common cancer, with a higher incidence than all other malignancies combined. Although it is rare to metastasize, patients with multiple or frequently recurring BCC can suffer substantial comorbidi...

see more →

Drugs  13 results see all →

Clinicaltrials.gov  3 results

Alteration of the Immune Microenvironment in Basal Cell Carcinoma Following Photodynamic Therapy
https://clinicaltrials.gov/ct2/show/NCT05020912

Aug 25th, 2021 - PDT is a technique that works by combining a photosensitizing topical agent and an intense light to kill tumor cells. PDT is not currently approved for the treatment of BCC by the Food and Drug Administration (FDA), although it is approved for tha...

A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
https://clinicaltrials.gov/ct2/show/NCT01327053

Aug 28th, 2019 - This study assessed the efficacy and safety of oral treatment with two dose levels of LDE225 in patients with locally advanced or metastatic BCC.

PEP005 Gel - Evaluation of the Safety and Efficacy of Ingenol Mebutate Gel on a Superficial Basal Cell Carcinoma on the Trunk or Extremities
https://clinicaltrials.gov/ct2/show/NCT01325688

Feb 26th, 2016 - This study is primarily designed to investigate whether treatment, once daily for up to three consecutive days, with PEP005 (ingenol mebutate) Gel, 0.05% will be safe and tolerable in patients with superficial Basal Cell Carcinoma (sBCC) lesions o...

see more →

News  276 results

Metformin Use May Curb BCC Risk
https://www.medscape.com/viewarticle/954839

Jul 15th, 2021 - Use of metformin was associated with a significant reduction in the risk of developing basal cell carcinoma (BCC), based on data from a population case-control study in Iceland. "In addition to general anticarcinogenic effects, metformin has also ...

EC Approves Cemiplimab for Advanced or Metastatic BCC After HHI Therapy
https://www.medscape.com/viewarticle/953892

Jun 28th, 2021 - The European Commission (EC) has approved cemiplimab (Libtayo) for the treatment of adults with locally advanced or metastatic basal cell carcinoma (BCC) who progressed on — or could not tolerate — treatment with a hedgehog pathway inhibitor (HHI)...

Topical Histone Deacetylase Inhibitor Reduced BCC Size in Phase 2 Study
https://www.medscape.com/viewarticle/953042

Jun 14th, 2021 - In the first clinical trial of a topical histone deacetylase (HDAC) inhibitor, remetinostat showed clinical efficacy across several basal cell carcinoma (BCC) tumor types, according to research presented at the annual meeting of the Society for In...

EU Panel Likes Monotherapy Cemiplimab for Two Cancers
https://www.medscape.com/viewarticle/951786

May 25th, 2021 - The immunotherapy cemiplimab (Libtayo) looks set to have two further cancer indications in Europe: nonsmall cell lung cancer (NSCLC) and basal cell carcinoma (BCC). The European Medicines Agency's Committee for Medicinal Products for Human Use (CH...

Hedgehog Inhibitor Alternative Dosing Advantageous for BCC
https://www.medscape.com/viewarticle/948925

Apr 7th, 2021 - Many experts in the treatment of locally advanced or metastatic basal cell carcinoma (BCC) have embraced alternative off-label dosing schedules for the oral hedgehog pathway inhibitors in a successful effort to maintain efficacy while reducing tre...

see more →

Patient Education  2 results see all →